Swedish Orphan Biovitrum AB: Elocta® Approved in Kuwait for the Treatment of Haemophilia A
Swedish Orphan Biovitrum AB: Elocta® Approved in Kuwait for the Treatment of Haemophilia A STOCKHOLM–(BUSINESS WIRE)– Swedish Orphan Biovitrum AB (publ) (SOBI.ST) (Sobi™) today announces that the Ministry of Health in Kuwait has approved Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A. Elocta is the first recombinant factor VIII Fc […]
Read more